The significance of different health institutions and their respective contributions of active pharmaceutical ingredients to wastewater

Environment International

Volumn 85, Issue , 2015, Pages 61-76

  Herrmann, Manuel ^a,b   Olsson, Oliver ^a   Fiehn, Rainer ^b   Herrel, Markus ^b   Kümmerer, Klaus ^a  

^a LEUPHANA UNIVERSITY OF LÜNEBURG   (Germany)

^b Klinikum Offenburg   (Germany)

Author keywords

Neurological drug; Nursing home; Pharmaceutical contribution; Psychiatric hospital; Wastewater concentration

Indexed keywords

APPLICATION PROGRAMMING INTERFACES (API); EFFLUENTS; NEUROLOGY; NURSING;

ACTIVE PHARMACEUTICAL INGREDIENTS; AQUATIC ENVIRONMENTS; DEMOGRAPHIC CHANGES; EMISSION POTENTIAL; NEUROLOGICAL DRUG; NURSING HOMES; PSYCHIATRIC DISEASE; WASTEWATER CONCENTRATION;

HOSPITALS;

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMISULPRIDE; ANTICONVULSIVE AGENT; CEFUROXIME; CENTRAL DEPRESSANT AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; CLOMETHIAZOLE; DICLOFENAC; DOXEPIN; ETIRACETAM; FLUOROURACIL; FUROSEMIDE; GABAPENTIN; IBUPROFEN; LIDOCAINE; MEPIVACAINE; MESALAZINE; METFORMIN; METOPROLOL; MOCLOBEMIDE; PANTOPRAZOLE; PREGABALIN; QUETIAPINE; SIMVASTATIN; SULFAMETHOXAZOLE; UNINDEXED DRUG; VALSARTAN; DRUG; WASTE WATER; WATER POLLUTANT;

CONCENTRATION (COMPOSITION); DRUG; EFFLUENT; HOSPITAL SECTOR; METHODOLOGY; WASTEWATER;

AQUATIC ENVIRONMENT; ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DRUG USE; EFFLUENT; GENERAL HOSPITAL; GERMANY; HEALTH CARE FACILITY; HOUSEHOLD; MENTAL HOSPITAL; NURSING HOME; PREDICTION; PRIORITY JOURNAL; WASTE WATER; ANALYSIS; CHEMISTRY; DRUG UTILIZATION; HOSPITAL; HUMAN; TRENDS; WATER POLLUTANT;

GERMANY;

APIS;

DRUG UTILIZATION; GERMANY; HOSPITALS; HUMANS; NURSING HOMES; PHARMACEUTICAL PREPARATIONS; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84940472147     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2015.07.020     Document Type: Article

References (69)

1. Al Aukidy M., Verlicchi P., Jelic A., Petrovic M., Barcelò D. Monitoring release of pharmaceutical compounds: occurrence and environmental risk assessment of two WWTP effluents and their receiving bodies in the Po Valley, Italy. Sci. Total Environ. 2012, 438:15-25.
2. AstraZeneca Pharmaceuticals Seroquel FDA Approved Label [internet document], (accessed June 30, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020639s061lbl.pdf.
3. Beier S., Cramer C., Köster S., Mauer C., Palmowski L., Schröder H.F., Pinnekamp J. Full scale membrane bioreactor treatment of hospital wastewater as forerunner for hot-spot wastewater treatment solutions in high density urban areas. Water Sci. Technol. 2011, 63:66-71.
4. Bergheim M., Kümmerer K. Ready biodegradability of valproic acid in the Closed Bottle Test 2007, (Unpublished raw data).
5. Capdeville M., Budzinski H. Trace-level analysis of organic contaminants in drinking waters and groundwaters. TrAC Trends Anal. Chem. 2011, 30:586-606.
6. Cheplapharm Arzneimittel GmbH Aponal 100 Summary of Product Characteristics, [internet document], (accessed June 30, 2015, [in German]). http://www.fachinfo.de.
7. Coetsier C., Spinelli S., Lin L., Roig B., Touraud E. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ. Int. 2009, 35:787-792.
8. EMEA: Committee for Medicinal Products for Human Use (CHMP) Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use 2006.
9. Escher B.I., Baumgartner R., Koller M., Treyer K., Lienert J., McArdell C.S. Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res. 2011, 45:75-92.
10. Federal Health Report Germany Hospitals, rehab clinics and hospitalization: classification: Germany, types of facilities [internet document], (accessed June 04, 2015, [in German]). https://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/WS0100/_XWD_FORMPROC?TARGET=&PAGE=_XWD_108&OPINDEX=1&HANDLER=_XWD_CUBE.SETPGS&DATACUBE=_XWD_136&D.000=3734.
11. Federal Health Report Germany, 2014b. People in need of long-term care: classification: year, region, age, sex, long-term care level, type of care [internet document], https://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/&p_aid=i&p_aid=4717275&nummer=834&p_sprache=D&p_indsp=-&p_aid=10150559 (accessed June 04, 2015, [in German]).
12. Federal Health Report Germany General hospitals: hospital statistics according to DESTATIS [internet document], (accessed June 04, 2015, [in German]). http://www.gbe-bund.de/gbe10/abrechnung.prc_abr_test_logon?p_uid=gasts&p_aid=&p_knoten=FID&p_sprache=D&p_suchstring=2034:Krankenhausbedarfsplan.
13. Federal Health Report Germany Other hospitals: hospital statistics according to DESTATIS [internet document], (accessed June 04, 2015, [in German]). http://www.gbe-bund.de/gbe10/abrechnung.prc_abr_test_logon?p_uid=gastg&p_aid=&p_knoten=FID&p_sprache=D&p_suchstring=9565:Krankenh%E4user,%20Krankenhaus.
14. Federal Ministry of Health Statutory health insurance - yearly average 2010: members and insured relatives. (accessed June 30, 2015, [in German]). http://www.bmg.bund.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder__Versicherte/KM1_Jahresdurchschnitt_2010.pdf.
15. Federal Ministry of Health Statutory health insurance - yearly average 2011: members and insured relatives (accessed June 30, 2015, [in German]). https://www.bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder__Versicherte/KM1_Jahresdurchschnitt_2011.pdf.
16. Federal Ministry of Health Statutory health insurance - yearly average 2012: members and insured relatives (accessed June 30, 2015, [in German]). http://www.bmg.bund.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_JD_2012.pdf.
17. Federal Statistical Office DESTATIS Statistics for people in need of long-term care 2011: Care in terms of the nursing care insurance - results for Germany [internet document], (accessed June 04, 2015, [in German]). https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Pflege/PflegeDeutschlandergebnisse5224001119004.pdf?__blob=publicationFile.
18. Federal Statistical Office DESTATIS State & Society - population based on census 2011 [internet document], (accessed June 04, 2015, [in German]). https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Bevoelkerungsstand/Tabellen/Zensus_Geschlecht_Staatsangehoerigkeit.html.
19. Federal Statistical Office DESTATIS Selected socio-demographic data (employment, education, migration background, religion): Zensus 2011 [internet document], (accessed June 04, 2015, [in German]). https://www.destatis.de/DE/PresseService/Presse/Pressekonferenzen/2013/Zensus2011/soziodemo_excel.xls;jsessionid=E4968163276567EFF6941E2D2A861C45.cae4?__blob=publicationFile.
20. Federal Statistical Office DESTATIS Water management: water supply from 1991 to 2010 [internet document], (accessed June 17, 2015). https://www.destatis.de/DE/ZahlenFakten/GesamtwirtschaftUmwelt/Umwelt/UmweltstatistischeErhebungen/Wasserwirtschaft/Tabellen/Wasserabgabe1991_2010.html.
21. Gasser G., Rona M., Voloshenko A., Shelkov R., Lev O., Elhanany S., et al. Evaluation of micropollutant tracers. II. Carbamazepine tracer for wastewater contamination from a nearby water recharge system and from non-specific sources. Desalination 2011, 273:398-404.
22. Gómez M.J., Petrović M., Fernández-Alba A.R., Barceló D. Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters. J. Chromatogr. A 2006, 1114:224-233.
23. Gupta P., Mathur N., Bhatnagar P., Nagar P., Srivastava S. Genotoxicity evaluation of hospital wastewaters. Ecotoxicol. Environ. Saf. 2009, 72:1925-1932.
24. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36:357-393.
25. Hamerschlak N., Cavalcanti A.B. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med. J. 2005, 123:247-249.
26. Heberer T., Feldmann D. Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents-modeling versus measurements. J. Hazard. Mater. 2005, 122:211-218.
27. Hedenmalm K., Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur. J. Clin. Pharmacol. 2002, 58:265-274.
28. Huber M., Andersohn F., Bronder E., Klimpel A., Thomae M., Konzen C., et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur. J. Clin. Pharmacol. 2014, 70:339-345.
29. Janssens H., Clays E., de Clercq B., Casini A., de Bacquer D., Kittel F., et al. The relation between psychosocial risk factors and cause-specific long-term sickness absence. Eur. J. Pub. Health 2014, 24:428-433.
30. Johnson A.C., Ternes T., Williams R.J., Sumpter J.P. Assessing the concentrations of polar organic microcontaminants from point sources in the aquatic environment: measure or model?. Environ. Sci. Technol. 2008, 42:5390-5399.
31. Klosterhaus S.L., Grace R., Hamilton M.C., Yee D. Method validation and reconnaissance of pharmaceuticals, personal care products, and alkylphenols in surface waters, sediments, and mussels in an urban estuary. Environ. Int. 2013, 54:92-99.
32. Kümmerer K., Henninger A. Promoting resistance by the emission of antibiotics from hospitals and households into effluent. Clin. Microbiol. Infect. 2003, 9:1203-1214.
33. Laidlaw K., Pachana N.A. Aging, mental health, and demographic change: challenges for psychotherapists. Prof. Psychol. Res. Pract. 2009, 40:601-608.
34. Langford K.H., Thomas K.V. Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works. Environ. Int. 2009, 35:766-770.
35. Le Corre K.S., Ort C., Kateley D., Allen B., Escher B.I., Keller J. Consumption-based approach for assessing the contribution of hospitals towards the load of pharmaceutical residues in municipal wastewater. Environ. Int. 2012, 45:99-111.
36. Liebig M., Moltmann J.F., Knacker T. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products. Environ. Sci. Pollut. Res. Int. 2006, 13:110-119.
37. Magee H.F. The Hospital Data Project: comparing hospital activity within Europe. Eur. J. Pub. Health 2003, 13:73-79.
38. Matamoros V., Duhec A., Albaiges J., Bayona J.M. Photodegradation of carbamazepine, ibuprofen, ketoprofen and 17 alpha-ethinylestradiol in fresh and seawater. Water Air Soil Pollut. 2009, 196:161-168.
39. Morasch B., Bonvin F., Reiser H., Grandjean D., de Alencastro, Felippe L., Perazzolo C., et al. Occurrence and fate of micropollutants in the Vidy Bay of Lake Geneva, Switzerland. Part II: micropollutant removal between wastewater and raw drinking water. Environ. Toxicol. Chem. 2010, 29:1658-1668.
40. Morgan M.Y. The management of alcohol withdrawal using chlormethiazole. Alcohol Alcohol. 1995, 30:771-774.
41. Mullot J., Karolak S., Fontova A., Levi Y. Modeling of hospital wastewater pollution by pharmaceuticals: first results of Mediflux study carried out in three French hospitals. Water Sci. Technol. 2010, 62:2912.
42. Nikolaou A., Meric S., Fatta D. Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal. Bioanal. Chem. 2007, 387:1225-1234.
43. Oliveira T.S., Murphy M., Mendola N., Wong V., Carlson D., Waring L. Characterization of pharmaceuticals and personal care products in hospital effluent and waste water influent/effluent by direct-injection LC-MS-MS. Sci. Total Environ. 2015, 518-519:459-478.
44. Onesios K.M., Bouwer E.J. Biological removal of pharmaceuticals and personal care products during laboratory soil aquifer treatment simulation with different primary substrate concentrations. Water Res. 2012, 46:2365-2375.
45. Ort C., Lawrence M.G., Reungoat J., Eaglesham G., Carter S., Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res. 2010, 44(2):605-615.
46. Ortiz de García S., Pinto Pinto G., García Encina P., Irusta Mata R. Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain. Sci. Total Environ. 2013, 444:451-465.
47. Pfizer, Inc. Lyrica FDA Approved Label [internet document], (accessed June 30, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021446s029,022488s008lbl.pdf.
48. Pfizer, Inc. Neurontin FDA Approved Label [internet document], (accessed June 30, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020235s061,020882s044,021129s043lbl.pdf.
49. Ratiopharm GmbH Amisulpride Ratiopharm 400mg coated tablets Summary of Product Characteristics [internet document], (accessed June 30, 2015, [in German]). http://www.fachinfo.de.
50. Reungoat J., Macova M., Escher B.I., Carswell S., Mueller J.F., Keller J. Removal of micropollutants and reduction of biological activity in a full scale reclamation plant using ozonation and activated carbon filtration. Water Res. 2010, 44:625-637.
51. Reungoat J., Macova M., Escher B.I., Carswell S., Mueller J.F., Keller J. Removal of micropollutants and 5-6 ozonation and activated carbon filtration. Water Res. 2010, 44:625-637.
52. Schuster A., Hädrich C., Kümmerer K. Flows of active pharmaceutical ingredients originating from health care practices on a local, regional, and nationwide level in Germany-is hospital effluent treatment an effective approach for risk reduction?. Water Air Soil Pollut. Focus 2008, 8:457-471.
53. Schwabe U., Paffrath D. Pharmaceutical Prescription Report 2011: Current Data, Expenses, Trends and Comments 2011, Springer Verlag, Berlin, (in German).
54. Schwabe U., Paffrath D. Pharmaceutical Prescription Report 2012: Current Data, Expenses, Trends and Comments 2012, Springer Verlag, Berlin, (in German).
55. Schwabe U., Paffrath D. Pharmaceutical Prescription Report 2013: Current Data, Expenses, Trends and Comments 2013, Springer Verlag, Berlin, [in German].
56. Singh K.P., Rai P., Singh A.K., Verma P., Gupta S. Occurrence of pharmaceuticals in urban wastewater of north Indian cities and risk assessment. Environ. Monit. Assess. 2014, 186:6663-6682.
57. Truven Health Analytics Inc. Micromedex Database 2.0 2013.
58. UCB, Inc. Keppra FDA Approved Label [internet document], (accessed June 30, 2015). http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021035s093,021505s033lbl.pdf.
59. van der Aa N.G., Kommer G.J., van Montfoort J.E., Versteegh J.F.M. Demographic projections of future pharmaceutical consumption in The Netherlands. Water Sci. Technol. 2011, 63:825.
60. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment-a review. Sci. Total Environ. 2012, 429:123-155.
61. Verlicchi P., Al Aukidy M., Galletti A., Petrovic M., Barceló D. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci. Total Environ. 2012, 430:109-118.
62. Verlicchi P., Al Aukidy M., Jelic A., Petrović M., Barceló D. Comparison of measured and predicted concentrations of selected pharmaceuticals in wastewater and surface water: a case study of a catchment area in the Po Valley (Italy). Sci. Total Environ. 2014, 470-471:844-854.
63. Weissbrodt D., Kovalova L., Ort C., Pazhepurackel V., Moser R., Hollender J., et al. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environ. Sci. Technol. 2009, 43:4810-4817.
64. WHOCC - structure and principles, WHO Collaborating Centre for Drug Statistics Methodology, [internet document], (accessed June 04, 2015). http://www.whocc.no/atc/structure_and_principles/.
65. WHOCC - definitions and general considerations, WHO Collaborating Centre for Drug Statistics Methodology, [internet document], (accessed June 04, 2015). http://www.whocc.no/ddd/definition_and_general_considera/.
66. WHO Health Impact Assessment (HIA): the determinants of health [internet document], (accessed June 04, 2015). http://www.who.int/hia/evidence/doh/en/.
67. Yu J.T., Bouwer E.J., Coelhan M. Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agric. Water Manag. 2006, 86:72-80.
68. Yu J.T., Bisceglia K.J., Bouwer E.J., Roberts A.L., Coelhan M. Determination of pharmaceuticals and antiseptics in water by solid-phase extraction and gas chromatography/mass spectrometry: analysis via pentafluorobenzylation and stable isotope dilution. Anal. Bioanal. Chem. 2012, 403:583-591.
69. Yuan S., Jiang X., Xia X., Zhang H., Zheng S. Detection, occurrence and fate of 22 psychiatric pharmaceuticals in psychiatric hospital and municipal wastewater treatment plants in Beijing, China. Chemosphere 2013, 90:2520-2525.